ConsumerAffairs

Medicare negotiates new prices for Ozempic and Wegovy

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic

Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid ...
Becker's Hospital Review

Medicare to cover GLP-1s under Trump-negotiated pricing

Medicare cover GLP-1s under a Trump-negotiated pricing plan starting in 2026, lowering costs for key obesity and diabetes drugs.

Certain obesity drugs will cost as little as $149 and Medicare will start covering them under White House deals

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...
Opinion

Medicare Can’t Afford Not To Cover Ozempic

America's obesity epidemic costs an estimated $173 billion each year. The benefits of covering GLP-1s vastly outweigh the costs.

Medicare to Cover GLP-1 Drugs for as Little as $50 a Month Under Trump Plan

Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.
Zacks.com on MSN

Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.